National
Behind the scenes of the Obama campaign
LGBT staffers take key roles in 2012 effort
President Obama (Blade file photo by Michael Key)
[Editor’s note: This is the second of a two-part series.]
Gay and lesbian staffers have taken key roles ranging from public outreach to battleground state strategy in the campaign already underway to re-elect President Obama to the White House in 2012.
The Washington Blade interviewed four gay and lesbian staffers working to re-elect Obama from the campaign headquarters in Chicago. This article is the second in a two-part series and features interviews with two of the campaign workers: Jamie Citron, LGBT vote director for Project Vote, and Karine Jean-Pierre, deputy battleground states director.
As LGBT vote director for Project Vote, Citron, who’s 28 and gay, is focused on monitoring the news developments and needs of the LGBT community. Established in August, Project Vote is the Obama campaign’s initiative aimed at encouraging participation among Democratic base constituencies, including LGBT Americans.
“Usually when I first make it into the office, it’s trying to catch up on the community,” Citron said. “It’s seeing what the conversations are, what the buzz was overnight on the listservs. It’s about reading the blogs and reading the LGBT press and seeing what the top lines of the stories are today.”
Other daily duties for Citron are meeting with the rest of the Project Vote team to discuss the best ways for taking the Obama campaign’s messages to the Democratic Party’s constituencies — as well as integrating the concerns of those constituencies into the campaign.
“Most important to me in my mind, each of us kind of figures out how we can work together across constituencies and make sure that we are engaging people as whole people instead of just focusing on one block at a time,” Citron said.
Citron’s role with the Obama campaign is similar to his previous role at the Democratic National Committee, where he served as director of the LGBT leadership council. Citron, who was also involved in the 2008 campaign, said he transferred back to the campaign to take a more direct role in the “engine working the campaign” to re-elect Obama.
A Chicago native, Citron said he also wanted to return to the Windy City to be closer to his boyfriend of three years, Tyler, who’s 30 and a lawyer living in the area. The two met in 2007 at an Obama fundraiser. Citron asked that Tyler’s last name be withheld.
The scope of Jean-Pierre’s role is somewhat larger as she develops campaign strategy for the battleground states in 2012. A key task: providing resources to states and figuring out the best way for them to get the word out for the campaign.
“To me, getting the president re-elected right now is the most important thing that I can be doing with my life,” Jean-Pierre said.
Jean-Pierre’s role is similar to her duties in 2008 as the Obama campaign’s southern political director. Upon Obama’s election, Jean-Pierre, a lesbian, became White House liaison to the Labor Department and later became regional director in the White House Office of Political Affairs.
For Jean-Pierre, the decision to work as part of the 2012 campaign as opposed to staying at the White House was an easy one.
Under the Obama administration, the LGBT community has seen significant achievements, including passage an expanded federal hate crimes law and repeal of “Don’t Ask, Don’t Tell.” In February, Obama declared that the Defense of Marriage Act is unconstitutional — after initially defending the anti-gay law in court — and has been filing legal briefs against the statute.
Still, Obama has yet to fulfill all promises to the LGBT community on which he campaigned in 2008. One notable outstanding goal is passage of the Employment Non-Discrimination Act. Obama’s lack of support of same-sex marriage continues to disappoint LGBT advocates.
But those working on the Obama campaign maintain has been a friend to the community and will continue to be an LGBT advocate during a second term in office.
As a recent example of support, Citron cited the news of the Obama administration reasserting that DOMA is unconstitutional in a legal brief against the anti-gay statute in the case of Windsor v. United States as well as an announcement that the Department of Homeland Security will work to take foreign nationals in same-sex relationships out of the deportation pipeline.
“I think the conversation between the LGBT community and the president certainly has been robust over the three years, and I think a lot of good things have come out about it,” Citron said. “Is the conversation finished? No. But I think it’s important that we acknowledge all that has come out from that and all that continues to come out.”
Campaign workers may also have their work cut out for them in convincing the general public to send the president back to the White House. According to recent polls, Obama’s approval ratings are at an all-time low. A Gallup poll published over the weekend found the president’s approval rating stands at just 42 percent.
Citron maintained LGBT people should be part of the effort to re-elect Obama.
“I think that the LGBT community could agree with me when I say I know that a second Obama term means more forward progress, whereas with a Republican entering the White House in 2012, not only does that signal the end to that progress, but it signals the start of a backwards march,” Citron said. “I think that’s something we should all be concerned about.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
